Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
396 articles by Ben Fidler
-
Another Astellas gene therapy trial paused by FDA after side effect report
June 27, 2022 -
FDA suspends US testing of Sarepta Duchenne drug over safety concerns
June 23, 2022 -
Bristol Myers CAR-T therapy cleared by FDA for earlier lymphoma use
June 23, 2022 -
Ionis, AstraZeneca claim success for competitor to Alnylam rare disease drug
June 21, 2022 -
FDA advisers recommend Pfizer, Moderna COVID-19 vaccines for youngest children
June 15, 2022 -
Alnylam wins FDA approval of rare disease drug in step toward profitability
June 14, 2022 -
Latest Caribou data add to 'off-the-shelf' cell therapy's durability questions
June 10, 2022 -
Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
June 7, 2022 -
ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy
June 6, 2022 -
'Dramatic' study results for AstraZeneca, Daiichi drug suggest new way to treat aggressive breast cancer
June 5, 2022 -
GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine
May 31, 2022 -
Adicet data hints at early promise for 'gamma delta' cell therapy
May 27, 2022 -
3 cancer drug studies to watch at next month's ASCO meeting
May 26, 2022 -
Seagen CEO Siegall resigns amid domestic violence investigation
May 16, 2022 -
Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class
May 11, 2022 -
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
May 10, 2022 -
Clay Siegall, founding Seagen CEO, takes leave amid domestic violence accusation
May 9, 2022 -
FDA places stricter limits on J&J's COVID-19 vaccine after review of rare side effect
May 6, 2022 -
AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche
May 5, 2022 -
Spero to lay off 75% of workforce, change strategy after FDA challenges study results
May 4, 2022 -
Ionis, AstraZeneca change a key trial, fueling more questions about a genetic heart disease
May 2, 2022 -
FDA clears Pfizer to restart Duchenne gene therapy trial, with new safeguards
April 28, 2022 -
Two biotechs set out to end sector's IPO drought
April 27, 2022 -
Novartis names longtime analyst as top dealmaker amid organizational shakeup
April 26, 2022 -
Black Diamond, yielding to competitors, scraps its top drug and cuts jobs
April 25, 2022